Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction.
Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, Vandenwijngaert S, Dépelteau H, Streb W, Chaothawee L, Maes F, Gheysens O, Debyser Z, Gillijns H, Pellens M, Vandendriessche T, Chuah M, Collen D, Verbeken E, Belmans A, Van de Werf F, Bogaert J, Janssens S. Dubois C, et al. Among authors: van de werf f. J Am Coll Cardiol. 2010 May 18;55(20):2232-43. doi: 10.1016/j.jacc.2009.10.081. J Am Coll Cardiol. 2010. PMID: 20466204 Free article.
Tomographic and planar quantitation of perfusion defects on technetium 99m-labeled sestamibi scans: evaluation in patients treated with thrombolytic therapy for acute myocardial infarction.
Mortelmans LA, Wackers FJ, Nuyts JL, Scheys IA, Brzostek T, Schiepers CW, Lesaffre EE, Suetens PL, Verbruggen AM, Van de Werf FJ. Mortelmans LA, et al. Among authors: van de werf fj. J Nucl Cardiol. 1995 Mar-Apr;2(2 Pt 1):133-43. doi: 10.1016/s1071-3581(95)80024-7. J Nucl Cardiol. 1995. PMID: 9420778
A nonsurgical porcine model of left ventricular dysfunction. Validation of myocardial viability using dobutamine stress echocardiography and positron emission tomography.
Szilárd M, Mesotten L, Maes A, Liu X, Nuyts J, Bormans G, De Groot T, Pislaru S, Huang Y, Qiang B, Dispersyn GD, Borgers M, Flameng W, Van De Werf F, Mortelmans L, De Scheerder I. Szilárd M, et al. Among authors: van de werf f, de groot t, de scheerder i. Int J Cardiovasc Intervent. 2000 Jun;3(2):111-120. doi: 10.1080/14628840050516208. Int J Cardiovasc Intervent. 2000. PMID: 12470378
Defining the transmurality of a chronic myocardial infarction by ultrasonic strain-rate imaging: implications for identifying intramural viability: an experimental study.
Weidemann F, Dommke C, Bijnens B, Claus P, D'hooge J, Mertens P, Verbeken E, Maes A, Van de Werf F, De Scheerder I, Sutherland GR. Weidemann F, et al. Among authors: van de werf f, de scheerder i. Circulation. 2003 Feb 18;107(6):883-8. doi: 10.1161/01.cir.0000050146.66577.4b. Circulation. 2003. PMID: 12591760
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: van de werf f. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: van de werf f. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD. Janssens S, et al. Among authors: van de werf f. Circ Res. 2004 May 14;94(9):1256-62. doi: 10.1161/01.RES.0000126497.38281.23. Epub 2004 Mar 25. Circ Res. 2004. PMID: 15044322 Free article.
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
757 results